InsiderPulse| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-10 | 2026-03-10 | Ladiwala Shiraz Shabanali | Director | Purchase | 3,500 | $72.23 | $253K | 8,523 | View ↗ | |
| 2026-03-10 | 2026-03-10 | Capone Mark Christopher | Director | Purchase | 1,301 | $76.35 | $99K | 3,429 | View ↗ | |
| 2026-03-10 | 2026-03-10 | Tripeny R Tony | Director | Purchase | 1,315 | $76.00 | $100K | 5,398 | View ↗ |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenues | — | — | — | — | $26.9M |
| Revenue | $42.6M+8.1% | $39.4M+2.2% | $38.6M+10.4% | $34.9M-73.9% | $133.9M |
| Cost of revenue | $29.7M+15.3% | $25.7M+5.3% | $24.4M+19.3% | $20.5M+48.5% | $13.8M |
| Gross profit | $150.9M+13.2% | $133.3M-0.3% | $133.7M+22.6% | $109.1M+25.4% | $87.0M |
| Basic (loss) earnings per share (in dollars per share) | -$360+99.2% | -$47K-27864.7% | $170-52.8% | $360-45.5% | $660 |
| Diluted (loss) earnings per share (in dollars per share) | -$360+99.2% | -$47K-27864.7% | $170-51.4% | $350-45.3% | $640 |
| Selling | $41.7M+7.9% | $38.6M+3.2% | $37.4M+32.2% | $28.3M+53.2% | $18.5M |
| General and administrative, other than impairment of finite-lived intangible assets and goodwill | $73.3M+0.6% | $72.9M+0.6% | $72.4M+20.1% | $60.3M+31.7% | $45.8M |
| Research and development | $19.5M+1.1% | $19.3M-5.8% | $20.5M+30.0% | $15.8M+51.8% | $10.4M |
| Impairment of finite-lived intangible assets | $0-100.0% | $117.6M | $0 | $0 | — |
| Impairment of goodwill | $0-100.0% | $156.9M | $0 | $0 | — |
| Total operating expense | $134.5M-66.8% | $405.3M+210.9% | $130.4M+24.9% | $104.4M+39.8% | $74.7M |
| Operating income (loss) | $16.3M+106.0% | -$272.1M-8295.0% | $3.3M-29.4% | $4.7M-62.0% | $12.4M |
| Interest expense and amortization of debt issuance costs | $11.9M+108.2% | $5.7M+19.4% | $4.8M+22.8% | $3.9M | — |
| Gain on extinguishment of convertible senior notes | -$2.9M | $0 | $0 | — | — |
| Other expense (income), net | $1.4M+166.1% | -$2.1M-100.2% | -$1.1M+61.5% | -$2.8M-235.7% | $2.0M |
| Total nonoperating expense, net | $10.4M+190.4% | $3.6M-3.7% | $3.7M+228.8% | $1.1M-88.8% | $10.1M |
| Earnings (loss) before income taxes | $6.0M+102.2% | -$275.6M-70760.7% | -$389K-110.9% | $3.6M+55.2% | $2.3M |
| Income tax expense (benefit) | $7.9M+137.1% | -$21.4M-1522.6% | -$1.3M-177.5% | $1.7M+275.4% | -$971K |
| Net (loss) income | -$2.0M+99.2% | -$254.2M-27438.3% | $930K-50.3% | $1.9M-42.9% | $3.3M |
| Basic (in shares) | $5.4M+0.6% | $5.4M+1.2% | $5.3M+2.1% | $5.2M+4.8% | $5.0M |
| Diluted (in shares) | $5.4M+0.6% | $5.4M+0.5% | $5.4M+0.5% | $5.3M+4.1% | $5.1M |
| Product [Member] | |||||
| Revenues | — | — | — | — | $26.9M |
| Revenue | $42.6M+8.1% | $39.4M+2.2% | $38.6M+10.4% | $34.9M-73.9% | $133.9M |
| Cost of revenue | $29.7M+15.3% | $25.7M+5.3% | $24.4M+19.3% | $20.5M+48.5% | $13.8M |
| Service [Member] | |||||
| Revenues | — | — | — | — | $26.9M |
| Revenue | $42.6M+8.1% | $39.4M+2.2% | $38.6M+10.4% | $34.9M-73.9% | $133.9M |
| Cost of revenue | $29.7M+15.3% | $25.7M+5.3% | $24.4M+19.3% | $20.5M+48.5% | $13.8M |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Undervalued Small Caps With Insider Buying Across Regions To Consider
10 high-profitability small-cap stocks that are outperforming in 2026
MESA LABS DECLARES QUARTERLY DIVIDEND
Mesa Laboratories: Hard To Set The Right Diagnosis